Mikkael Sekeres

Mikkael Sekeres is a hematologist known for both his clinical research in MDS and his leadership in evidence-based oncology practice. He has contributed to clinical trials evaluating azacitidine plus venetoclax in higher-risk MDS and evaluation of novel combinations. His research examines shared decision-making processes in MDS, a condition that disproportionately affects older adults who require thoughtful treatment planning. He has led NHLBI-funded studies, served on FDA advisory committees, and written widely read patient education materials about MDS.